NASDAQ:AKCA - Akcea Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$18.17
+0.30 (1.20%)
Get New Akcea Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKCA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKCA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Akcea Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.17.

This chart shows the closing price for AKCA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Akcea Therapeutics. This rating has held steady since August 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2020BMO Capital MarketsLower Price Target$26.00 ➝ $18.15Low
8/31/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$26.00 ➝ $18.15Low
8/31/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal WeightHigh
8/9/2020CowenReiterated RatingHoldLow
2/26/2020CowenReiterated RatingHoldHigh
1/29/2020Needham & Company LLCReiterated RatingBuy$41.00Low
1/22/2020Needham & Company LLCReiterated RatingBuy$41.00Medium
11/6/2019CowenReiterated RatingHoldHigh
11/6/2019Needham & Company LLCReiterated RatingBuy$45.00High
10/8/2019BMO Capital MarketsLower Price TargetOutperform$43.00 ➝ $39.00Medium
10/7/2019Needham & Company LLCReiterated RatingBuy$45.00High
10/7/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
9/23/2019CowenReiterated RatingHoldHigh
9/23/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$44.00 ➝ $24.00High
8/7/2019BMO Capital MarketsSet Price TargetBuy$43.00Low
9/25/2018Stifel NicolausBoost Price TargetHold ➝ Hold$25.00 ➝ $31.00High
9/18/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$45.00High
9/2/2018CowenReiterated RatingHoldLow
8/28/2018Stifel NicolausLower Price TargetHold ➝ Hold$33.00 ➝ $25.00High
8/8/2018UBS GroupDowngradeBuy ➝ HoldLow
8/7/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $40.00High
8/7/2018Wells Fargo & CompanyBoost Price TargetOutperform$33.00 ➝ $46.00High
8/7/2018Stifel NicolausReiterated RatingHold$33.00High
5/11/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
5/4/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$42.00 ➝ $38.00N/A
3/19/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Market Perform$20.00High
3/16/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$20.00 ➝ $30.00High
3/15/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
2/27/2018BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$25.00 ➝ $30.00High
2/27/2018Stifel NicolausDowngradeBuy ➝ Hold$20.00High
2/27/2018CowenDowngradeOutperform ➝ Market PerformHigh
2/27/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$27.00High
11/7/2017Stifel NicolausReiterated RatingBuy ➝ Buy$19.00 ➝ $20.00N/A
10/31/2017CowenReiterated RatingBuyN/A
8/8/2017BMO Capital MarketsInitiated CoverageOutperform$25.00Medium
8/8/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$27.00Medium
8/8/2017CowenInitiated CoverageOutperformMedium
8/8/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$19.00Medium
(Data available from 1/26/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Akcea Therapeutics logo
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.
Read More

Today's Range

Now: $18.17
Low: $18.17
High: $18.17

50 Day Range

MA: $18.16
Low: $18.13
High: $18.17

52 Week Range

Now: $18.17
Low: $8.00
High: $21.70

Volume

N/A

Average Volume

361,806 shs

Market Capitalization

$1.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Akcea Therapeutics?

The following sell-side analysts have issued stock ratings on Akcea Therapeutics in the last year:
View the latest analyst ratings for AKCA.

What is the current price target for Akcea Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Akcea Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Akcea Therapeutics in the next year.
View the latest price targets for AKCA.

What is the current consensus analyst rating for Akcea Therapeutics?

Akcea Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AKCA.

How do I contact Akcea Therapeutics' investor relations team?

Akcea Therapeutics' physical mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company's listed phone number is 617-207-0202 and its investor relations email address is [email protected] The official website for Akcea Therapeutics is www.akceatx.com.